All posts by imreal

Gifford Bioscience Launch New SPR (Biacore) Assay Service


Macer Gifford, Managing Director added ‘’Biacore is a natural fit within the core competence of Gifford Bioscience: determining how a potential drug binds to its target. Kevin had considerable experience with the technique and we are delighted to have him lead the business stream.”

In January 2020, Birmingham based preclinical contract research organisation, Gifford Bioscience Limited, launched their new SPR Biacore Assay Service. This is a highly specialised technique, adding further depth to the company’s core competence in receptor pharmacology.

Who Is Gifford Bioscience?

Gifford Bioscience are based on the University of Birmingham’s Research Park, in the United Kingdom. They specialise in providing receptor pharmacology and occupancy studies to biotech companies, large pharma and university researchers.

Gifford Bioscience have quickly built a loyal international client base. Two-thirds of their contracts are repeat business from the scientists they have previously worked with. Half of their business comes from researchers in the United States and a further third from Continental Europe.

Gifford Bioscience is a family firm, founded by two brothers. Dr Andrew Gifford, Chief Scientific Officer, was previously Senior Scientist at Brookhaven National Laboratory in New York. Macer Gifford, Managing Director, was previously deputy CEO of a banking group. Dr Kevin Thompson joined last year, to develop the new business line, bringing with him 25-years’ experience in Biotech Pharma and specialist expertise in SPR (Biacore) Assays.

What are SPR (Biacore) Assays?

Gifford Bioscience’s new SPR (Biacore) Assay service involves immobilising a target receptor onto a biosensor surface in a Biacore T200 instrument. Test compounds are flowed over the biosensor surface to measure their binding and release from the receptor. This methodology is vital for optimising the affinity and receptor residency of candidate drug compounds.

The new service can be divided into two main parts:


  • Kinetic Affinity – Measuring the binding association rate of a compound with its target receptor and then its subsequent dissociation rate to calculate affinity. This technique also measures how long a compound remains bound to its receptor (residency).
  • Equilibrium Binding – For compounds with association and dissociation rates that are too fast to measure using the T200, receptor affinity can be determined from the equilibrium binding response at increasing compound concentrations.

By offering this new service, Gifford Bioscience hope to assist customers to advance their candidate drug selection and development programmes to bring more effective drugs to market more quickly.

What Else are Gifford Bioscience Doing?

Gifford Bioscience are a fast-growing scientific research business, but they adhere tightly to their core expertise in testing how and where a potential new medical drug binds to its intended target in the body.

The assay services currently offered by Gifford Bioscience include:

  • Receptor Occupancy – Assays that measure the degree to which a test substance occupies its target receptor in tissues or animals.
  • Radioligand Binding – These assays are considered the gold standard for measuring the affinity of ligand binding to a target receptor, due to their high levels of robustness and sensitivity.
  • Receptor Autoradiography – Used for identifying receptor binding sites and the distribution of radiolabelled drugs in tissue or organ sections.
  • Cellular Uptake and Release – Used to measure a compound’s transport into cells or efflux from cells. They can also determine a compound’s potency and efficacy.
  • Custom Radiolabelling – Small molecules, peptides and proteins can be custom radiolabelled by Gifford Bioscience, for use with their assay services.

Share article on social media or email:

NFP to Host Fourth Quarter 2019 Earnings Call on Feb. 14, 2020


News Image

NFP will host a live conference call to discuss the year-end results on Feb. 14, 2020 at 9:30 a.m. ET.

NFP, a leading insurance broker and consultant that provides employee benefits, property and casualty, retirement, and individual private client solutions, will post its year-end 2019 earnings results the evening of Feb. 13, 2020, to a password-protected website hosted by http://www.intralinks.com. In addition, NFP will host a live conference call to discuss the year-end results on Feb. 14, 2020 at 9:30 a.m. ET.

Interested parties can request access to NFP earnings results and the conference call by contacting NFP at ir@nfp.com or 212.301.1088.

About NFP

NFP is a leading insurance broker and consultant providing specialized property and casualty, corporate benefits, retirement and individual solutions through its licensed subsidiaries and affiliates. NFP enables client success through the expertise of over 5,600 global employees, investments in innovative technologies, and enduring relationships with highly rated insurers, vendors, and financial institutions. NFP is the 5th largest benefits broker by global revenue, 6th largest US-based privately owned broker, and 8th best place to work in insurance (Business Insurance); 10th largest property and casualty agency (Insurance Journal); and 13th largest global insurance broker (Best’s Review).

Visit NFP.com to discover how NFP empowers clients to meet their goals.

Share article on social media or email:

The Surge Institute welcomes new Vice President of National Programs


News Image

“In my career, I have never had the experience of working in an organization that’s comprised of all leaders of color, that’s pretty powerful!”

The national movement to elevate transformative leaders in education just entered a new chapter as education innovator Rodney Thomas begins a new journey leading program strategy as Vice President of National Programs at the Surge Institute. The role is critical in continuing to ensure sustainability for the Surge Institute’s current Surge Fellowship and Surge Academy sites as well as laying the programmatic groundwork for future expansion. The organization is thrilled to be adding to the phenomenal energy and heart of the Surge team to continue to drive impact and elevate leaders of color who are dedicated to serving the nation’s youth.

Rodney joins the Surge Institute with vast experience in the education, private and nonprofit sectors, most recently serving as a Senior Associate at the National Equity Project where he was responsible for designing and providing unique leadership and organizational development solutions that focused on technical, relational, social, and cultural aspects of complex change efforts focused on educational equity.

He began his career as an 8th grade teacher in Chicago Public Schools where he was honored as Teacher of the Year. After spending several years in the classroom, Rodney transitioned into the private sector and worked for companies such as Accenture, Motorola, and Unilever, with a focus on organizational development and design, executive coaching, change management and leadership development. Rodney later returned to Chicago Public Schools and was responsible for several large-scale projects from the implementation of Freshman On Track to the co-creation of The Chicago Leadership Collaborative, a principal training and support program.

“I’m most excited about having the opportunity to work with the amazing leaders who make up the Surge Institute,” said Thomas. In his new role, Rodney will set and execute the vision and direction for the content of the Surge Fellowship and Academy programs across all regions; he will design Surge core curriculum and work with regional program staff to ensure high-fidelity implementation. The role will also have a strong focus on introducing new, innovative program opportunities beyond the Surge Fellowship and Surge Academy, driving the Surge Institute into the future of what’s next within the fields of executive leadership and diversity, equity, and inclusion.

Thomas continued, “In my career, I have never had the experience of working in an organization that’s comprised of all leaders of color, that’s pretty powerful! As VP of National Programs, I’m also excited to play a part in co-designing the fellowship experience for Surge Fellows and see the impact of building leadership capacity for leaders of color across the US. Over the last few years, Surge has created a movement across the educational landscape and I’m super excited to be a member of this very special community.”

“Rodney has been a featured speaker for our Fellowship programming for a number of years and his unique blend of enthusiasm, deep expertise, humility, and unwavering commitment to the elevation and excellence of people of color make him an ideal formal addition to our team,” said Surge Institute Founder & President Carmita Semaan. “Rodney dreams big when he thinks about the future of Surge. And he pairs that passion for innovation and ingenuity with a keen appreciation for the systems, processes, and structures required to help us get there with high fidelity. The future of the Surge Institute has never been brighter and that future will inevitably be illuminated even further with this wonderful addition to our team.”

The Surge Institute is blessed to welcome Rodney Thomas to the team and looks forward to connecting and working to introduce the next facet of transformative executive leadership programming for emerging leaders of color.

About the Surge Institute:

The Surge Institute was established in 2014 with a simple but important mission to develop and elevate leaders of color who create transformative change for children, families, and communities. Founded by Carmita Semaan in 2014, the organization’s signature program, the Surge Fellowship, was designed to empower emerging diverse leaders to change the landscape of education by providing them with a unique, authentic leadership development experience.

To learn more about The Surge Institute, please visit: https://www.surgeinstitute.org/

Share article on social media or email:

5-Year Follow-Up Outpatient of L4-L5 Fixation with Inspan Device for Degenerative Spinal Stenosis Demonstrates Improved Results


The Inspan device from INSPAN, LLC

INSPAN LLC (a privately-owned company) is pleased to announce the successful results from a long-term follow-up clinical study of outpatient L4-L5 lumbar interspinous fixation for degenerative spinal stenosis using the Inspan interspinous fixation device (INSPAN LLC). Unlike extension block design, the Inspan device fixates the spine to allow for immediate stability, distraction, decompression, and fusion. Based on biomechanical studies, the Inspan device may be the strongest interspinous fixation device on the market and thus is being used for spinal fusion replacing the traditional method that uses pedicle screws and interbodies with laminectomies

The study was performed at the LESS Institute by Professor Dr. Kingsley R Chin, MD, a board-certified orthopedic spine surgeon and coauthors Dr. Fabio Pencle and Dr. Jason Seale.

The study was a retrospective review of prospectively collected data under an IRB approved study cohort. The study evaluated 122 surgical cases of lumbar decompression with interspinous fixation from September 2011 to October 2016. A total of 56 patients had instrumentation at L4-L5. Total female population was 46%. The median age of the patients included in the population was 50.9+/-10.7 years with a median BMI of 24.8+/-11.4 kg/m2. Two-year VAS and ODI showed significant improvement form 8.1+/-1.2 to 1.5+/-1.1 and 42.9+/-14.3 to 14.8+/-5.1. All surgeries were completed in less than one hour. There was a total of one revision case with removal of Inspan and converted to an open hemilaminectomy decompression.

In conclusion, the long-term outcome of the study demonstrated improved outcomes in patients who underwent interspinous distraction decompression in an ambulatory surgery center using the Inspan device at L4-L5 for degenerative spinal stenosis. There were no complications or implant failures.

About INSPAN, LLC

INSPAN, LLC is privately owned by KICVentures and is focused on advancing the platform of patented interspinous fixation technology. The Inspan device has a proven ten-year track record with thousands implanted since FDA-clearance in 2010.

Inspan FDA Indications

The Inspan Slim Spinous Process Plate System is a posterior non-pedicle supplemental fixation system intended for use in the non-cervical spine (T1-S1). It is intended for plate fixation/attachment to the spinous process for the purpose of achieving supplemental fusion for the following indications: spondylolisthesis, trauma (fracture ordislocation), tumor, or degenerative disc disease (defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies). The device is intended for use with bone graft material and is not intended for stand-alone use.

Share article on social media or email:

Professional Conflict Mediator Empowers Readers to Write Their Own Story to the Very End in Informative New Guidebook ‘How to Live Forever’


News Image

In my time mediating clients and working as a nurse, I have seen so many people leave behind many unresolved issues which led to undue stress and pain for the client and family members. With my book, I wanted to help provide a path to a better ending.

Our lives are a long and wonderful story, full of highs, lows and milestones, and we have the power to end our life story on our terms and leave behind a dignified legacy. Professional conflict mediator and author Kimberly Best teaches readers how to finish their own stories well in her encouraging new book “How to Live Forever: A Guide to Writing the Final Chapter of Your Life Story.”

Best empowers readers to take control of their destinies by recognizing the life they live creates their story which turns into their legacy so they can be purposeful in writing that story to the very end. Through true stories and with questions and prompts, the book guides readers to not only leave behind the actual story of their lives but to make personal choices around legal and health care decisions as well as their end of life ceremony and relationships.

“How to Live Forever” asserts that learning how to finish life well will ultimately help readers share the gift of their final wishes with their loved ones. Best’s book empowers readers to put the fear of death behind them and come to terms with the reality of death so they can celebrate life and walk through the end of life with clarity, courage and compassion. Through her book, Best seeks to bring people together during a time that typically can tear families apart as she discusses the benefits of mediation as a vital resource in navigating the difficult conversations around the last chapter of life.

“It is past time to take away the taboo and to have these difficult, yet freeing discussions around the second most important event in our life – our death,” says Best. “In my time mediating clients and working as a nurse, I have seen so many people leave behind many unresolved issues which led to undue stress and pain for the client and family members. With my book, I wanted to help provide a path to a better ending.”

Endorsers such as Kenneth Cloke, mediator and arbitrator for the Center of Dispute Resolution and author of “The Crossroads of Conflict,” and Dr. John Trent, president of Christian organization Strong Families and author of “The Blessing” and “Life Mapping,” hail “How to Live Forever” as “a wonderful guide to gather memories and have those needed conversations” and a “seamless combination of stirring human stories, how-to lists, and sensible advice.” A reviewer with the American Bar Association called the book “a fast read and compact for all of the tips, tools, and resources it offers…Best offers sage advice and tips based on her work first as a registered nurse, and later as a mediator focusing on family conflict and elder care.”

“How to Live Forever: A Guide to Writing the Final Chapter of Your Life Story”

By Kimberly Best

ISBN: 9781973675334 (softcover); 9781973675341 (hardcover); 9781973675327 (electronic)

Available at WestBow Press, Amazon and Barnes & Noble

About the author

Kimberly Best, RN, MA is a professional mediator focusing on conflict coaching, family and elder mediation. She holds a master’s degree in conflict management from Lipscomb University. She spent her early career as a registered nurse in intensive care, trauma and emergency medicine where she gained valuable experience in the medical system. A mother and grandmother, Best currently lives in Franklin, Tennessee where she runs her mediation practice, Best Conflict Solutions. To learn more please visit http://www.bestconflictsolutions.com and follow her on Twitter, @kabest05.

Share article on social media or email:



WPI Researcher Shares 3D Roadmap of Coronavirus with Scientists Worldwide


WPI bioinformatics researcher Dmitry Korkin examines a 3D model of a key protein of the novel coronavirus.

WPI bioinformatics researcher Dmitry Korkin examines a 3D model of a key protein of the novel coronavirus.

“This is one of the first examples of how data-driven science can quickly respond to this challenge.”- Dmitry Korkin, associate professor of computer science

A Worcester Polytechnic Institute (WPI) bioinformatics researcher has created and unveiled a structural 3D roadmap of the new coronavirus (2019-nCoV), a major development that potentially holds the key to understanding the spread and treatment of the deadly virus.

Using a recently published viral genome of the Wuhan coronavirus made available on the National Center for Biotechnology Information website, Dmitry Korkin and a team of graduate students used molecular modeling to reconstruct the 3D structure of major viral proteins and their interactions with human proteins.

“We’re confident that our data and visual models could provide the guidance for experimental scientists worldwide who are working feverishly to solve this pandemic,” said Korkin, associate professor of computer science at WPI and director of the university’s bioinformatics and computational biology program.

In effect, Korkin said, he and his team have created a structural genomics map of the coronavirus that will be made available to researchers and anyone worldwide.

“Anyone can download our models, get any kind of information and use it for research,” he said. “This is one of the first examples of how data-driven science can quickly respond to this challenge.”

The complete 3D structural roadmap dataset and a manuscript preprint can be found at Korkin’s lab website, and will be available at bioRxiv, a free online archive and distribution service for unpublished preprints in the life sciences operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. Given the global concern over the new coronavirus, Korkin and researchers worldwide are using the website for rapid communication about the virus.

Korkin and his team used existing public databases to identify three different isolates, or pure cultures of bacteria, in Severe Acute Respiratory Syndrome (SARS), a virus identified in 2003 that also caused worldwide infection and significant deaths. These could be the source of the new virus. According to the World Health Organization, there have been more than 40,000 cases worldwide, with more than 900 deaths, mostly in China—numbers that have been increasing daily as international agencies work to stem the spread of the virus, which began in Wuhan, China, in late December.

“We found that those three SARS isolates are not just similar to each other, but remarkably similar to the new coronavirus,” he said. “In fact, one of the isolates shares between 95 to 100 percent of its protein sequences.”

In explaining the 3D model findings, Korkin theorizes that multiple inserts on the genome sequence—which he likened to teeth on a key—may show how this virus is different from other coronaviruses such as SARS and MERS. For instance, while some of the inserts may block human antibodies from interacting with the viral surface protein, structural analysis suggests that some antibodies are capable of interacting with it.

Extending the analogy, the wrong key is being used to try to open a door—the door that would allow human antibodies in to combat the virus.

Korkin and his team made two other significant findings. First, WPI identified where on its protein structures this coronavirus differs from SARS. Through this identification, they were able to understand the functional implications of these differences.

Second, Korkin was able to examine the drug candidates for SARS that exist in the public database, and able to pinpoint the potential drugs that could lead to the new coronavirus treatment.

Korkin says he believes this kind of data-driven approach will become the standard for helping to solve some of the world’s biggest health challenges, as in the case of the coronavirus treatment.

“I firmly believe that using a strong bioinformatics and data-driven approach to life sciences will increasingly become the way for the science community to react to immediate health threats,” said Korkin.

As a next step, Korkin will provide the research community with further insights into the evolutionary implications of this new virus.

Joining Korkin on the research are WPI PhD students Hongzhu Cui, Ziyang Gao, Ming Liu, Senbao Lu, all from China; Oleksandr Narykov from Ukraine; Suhas Srinivasan from India; master’s student Sun Mo of China and master’s Fulbright scholar Winnie Mkandawire of Malawi.

Contact:

Andy Baron, Associate Director of Public Relations

Worcester Polytechnic Institute

Worcester, Massachusetts

508-831-5916, ajbaron@wpi.edu

Colleen Wamback, Associate Director of Public Relations

Worcester Polytechnic Institute

Worcester, Massachusetts

508-831-6775, cbwamback@wpi.edu

Share article on social media or email:

SentryHealth Expands Partnership with Healthstat


SentryHealth Logo

Through this powerful combination of advanced analytics, innovative technology, and evidence-based programs, our patients with chronic conditions will benefit from improved health and well-being.

SentryHealth announced today the expansion of a partnership with Healthstat, a leading provider of onsite health clinics. Focused on leading innovation in the treatment of chronic disease, Healthstat will implement SentryHealth’s SaaS-based population health management software, Healthward® at its onsite employee health clinics. Healthward delivers greater insight into eligibility for chronic care management programs, streamlines the enrollment process, and assists in promoting ongoing employee participation.

Powered by Healthward, Healthstat clinicians will enjoy:


  • A robust rules engine that analyzes employee health data to determine eligibility for programs focused on improving health conditions like diabetes, high blood pressure, and high cholesterol.
  • A real-time, bi-directional integration between their electronic health records software, eClinicalWorks, which will streamline notification of eligibility and allow quick program enrollment directly from the patient’s health record.
  • Detailed data analysis and advanced reporting of participation and outcomes for continued population health improvement.

“We are excited to further our partnership with SentryHealth,” said Warren Hutton, Healthstat President and COO. “Through this powerful combination of advanced analytics, innovative technology, and evidence-based programs, our patients with chronic conditions will benefit from improved health and well-being.”

“There’s a growing need for population health management software that empowers health care providers to promote and encourage positive behavior change among at-risk populations,” stated SentryHealth President and CEO, J. Kevin Porter. “This partnership enables Healthstat providers to augment their clinical expertise with population health insights to develop patient-specific care plans that ensure the best possible outcomes.”

For more information about SentryHealth’s population health management software, visit the company’s website at http://www.sentryhealth.com. For more information about Healthstat’s onsite health clinics, visit the company’s website at http://www.healthstatinc.com.

About SentryHealth:

SentryHealth improves the health and well-being of employees and covered dependents while reducing costs for health care providers nationwide. Their unique, technology-driven approach is powered by Healthward, an innovative software platform that integrates advanced analytics, robust outreach functionality, and evidence-based clinical protocols and programs to drive higher utilization and deliver quality, value-based care. Learn more by visiting http://www.sentryhealth.com.

About Healthstat:

Headquartered in Charlotte, N.C., Healthstat, Inc. is a leading provider of onsite primary care, health-risk intervention, chronic care management and occupational medicine in employer facilities. Healthstat offers a nationally recognized, proprietary healthcare delivery model that centers on patient engagement to improve health and productivity and lower healthcare costs for employers and their employees. For more information, visit http://www.healthstatinc.com.

Share article on social media or email:

NFP Acquires Indemnis Trade Risk Management Limited, Bringing New Capabilities to Its Property and Casualty Business


News Image

“We are proud of what we’ve built and look forward to extending the reach of our specialized expertise in collaboration with NFP offices across the US and Canada,” said Tom Leonard, principal of Indemnis.

NFP, a leading insurance broker and consultant that provides property and casualty (P&C), corporate benefits, retirement, and individual solutions, today announced the acquisition of Indemnis Trade Risk Management Limited (Indemnis), in a transaction that closed on December 10, 2019.

Indemnis, headquartered in Toronto, Ontario, Canada with operations in both Canada and the US, is a P&C broker focused on trade credit and political risk insurance. The firm’s consultative approach helps clients protect against catastrophic credit loss, while improving liquidity and financing arrangements, expanding sales safely to new segments, countries, and customers, strengthening trade risk management controls, and managing complex political risks. Tom Leonard, principal of Indemnis, will serve as the practice leader for NFP’s Trade Credit & Political Risk division.

“I’m excited to welcome Indemnis to NFP as we continue to expand our specialized P&C capabilities,” said Henry Lombardi, executive vice president and head of NFP’s Property and Casualty division. “As we continue to grow our presence in North America, we are working to enhance the support we provide to clients with global operations. The solutions that Tom and his team are able to deliver, will make our clients more resilient and support their ability to grow their businesses.”

“We are thrilled to join NFP and contribute to their continued growth in the specialty P&C space,” said Tom Leonard, principal of Indemnis. “We are proud of what we’ve built and look forward to extending the reach of our specialized expertise in collaboration with NFP offices across the US and Canada.”

About NFP

NFP is a leading insurance broker and consultant providing specialized property and casualty, corporate benefits, retirement and individual solutions through its licensed subsidiaries and affiliates. NFP enables client success through the expertise of over 5,600 global employees, investments in innovative technologies, and enduring relationships with highly rated insurers, vendors, and financial institutions. NFP is the 5th largest benefits broker by global revenue, 6th largest US-based privately owned broker, and 8th best place to work in insurance (Business Insurance); 10th largest property and casualty agency (Insurance Journal); and 13th largest global insurance broker (Best’s Review).

Visit NFP.com to discover how NFP empowers clients to meet their goals.

Share article on social media or email:

Axiom Bank, N.A. Appoints Susan Maurer as SVP, Market Executive


Susan has a passion for leadership, a keen business acumen and a huge amount of financial knowledge.

Axiom Bank N.A., a Maitland-based, leading community bank, recently named Susan Maurer as SVP, Market Executive. In this role, Maurer will develop relationships with Axiom’s commercial partners and create opportunities for growth in the Tampa Bay area.

With over four decades of experience working in financial institutions, Maurer specializes in business and community leadership, corporate lending, commercial relationship development and financial management.

“Susan has a passion for leadership, a keen business acumen and a huge amount of financial knowledge – and her stellar track record shows she can put her skills into action,” said Ted Sheppe, Executive Vice President, Commercial Banking of Axiom Bank. “That expertise will be a major advantage, not only for Axiom’s team, but also for the businesses we serve.”

Maurer earned her bachelor’s degree in banking and finance at National University and is pursuing a master’s degree at Southeastern University. In 2017, Maurer was a finalist for Tampa Bay Business Journal’s “Business Woman of the Year.”

For more information about Axiom Bank and to find the nearest location, visit AxiomBanking.com.

About Axiom Bank

Axiom Bank, a nationally chartered bank headquartered in Central Florida, serves the financial needs of its customers through a wide range of banking solutions and a commitment to exceptional service. The bank has a rich history dating back to 1963. By definition, “axiom” means “a universally recognized truth” – the name exemplifies the bank’s principles of truth, trust, value, convenience, and service excellence. Axiom Bank holds the SBA Preferred Lender status, and specializes in commercial loans, treasury management and other merchant services. The bank also offers asset-based lending and invoice factoring through its division, Allied Affiliated Funding. Axiom is constantly working to expand its services and products and provides consumer banking through over 20 branches, primarily in select Walmart Supercenters®, to conveniently serve local communities. Visit http://www.AxiomBanking.com. Member FDIC. Equal Housing Lender.

###

Share article on social media or email:

Aspire Regenerative Makes Available FDA-Approved EMSculpt Procedure in San Diego


Aspire Regenerative

Aspire Regenerative

Aspire Regenerative, a premiere regenerative medical practice in San Diego, CA, is now offering EMSculpt treatments to patients.

EMSculpt is an FDA-approved treatment designed to burn fat and build muscle tissue. It is currently approved to treat the abdomen, buttocks, thighs, calves, biceps, and triceps. The EMSculpt machine utilizes HIFEM® (High-Intensity Focused Electromagnetic) technology to stimulate intense supramaximal muscle contractions at a rate of approximately 20,000 contractions in one 30 minute treatment session.

Intense contractions of the skeletal muscles catalyze a fat-burning process known as lipolysis, where stored fat cells are released, metabolized, and eventually excreted naturally. Clinical studies found that on average, patients who receive EMSculpt experience a 19% reduction of fat and a five times increase in fat metabolism (their apoptotic index increased from 19% to 92% post treatment).

EMSculpt is the only body-contouring therapy currently available that not only targets fat burning but also strengthens muscle tissue. Because of this, EMSculpt can be used to improve joint posture and stability. It has also shown to be an effective treatment for diastasis recti, reducing muscle separation caused by this condition by 11%. Studies have found that patients who undergo EMSculpt treatments typically experience a 16% increase in muscle mass.

EMSculpt treatments are non-invasive and do not affect the skin above the muscle tissue. During treatment sessions, patients lie down on a table and EMSculpt machine paddles are placed above the targeted muscle group. The paddles are secured in place with an elastic band that wraps around the body and velcros in place. Treatments consist of 3 phases of muscle contractions that increase in intensity based on the individual patient’s comfort level.

A complete EMSculpt treatment regimen typically consists of 4 – 30 min treatments spread out over a period of 2 to 3 weeks. Patients can resume their usual activities immediately after treatment sessions, and there are no post-care procedures they need to follow. This makes EMSculpt far more convenient and less imposing than invasive procedures such as liposuction, implants, or butt lifts, which seek to deliver comparable body-contouring results. For more information on EMSculpt treatments, visit https://aspireregenerativehealth.com/services/emsculpt/.

Aspire Regenerative is a San Diego medical practice offering personalized regenerative treatments and integrative therapies focused on helping patients reach their goals and achieve their best possible results. Aspire Regenerative’s state-of-the-art facility is located at 4510 Executive Drive, Ste 111, San Diego, CA 92121. For more information, visit https://aspireregenerativehealth.com/.

Share article on social media or email: